Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P-glycoprotein

Journal of Cellular Physiology
Yaoting SunKexin Liu

Abstract

Though the advancement of chemotherapy drugs alleviates the progress of cancer, long-term therapy with anticancer agents gradually leads to acquired multidrug resistance (MDR), which limits the survival outcomes in patients. It was shown that dihydromyricetin (DMY) could partly reverse MDR by suppressing P-glycoprotein (P-gp) and soluble resistance-related calcium-binding protein (SORCIN) independently. To reverse MDR more effectively, a new strategy was raised, that is, circumventing MDR by the coadministration of DMY and ondansetron (OND), a common antiemetic drug, during cancer chemotherapy. Meanwhile, the interior relation between P-gp and SORCIN was also revealed. The combination of DMY and OND strongly enhanced antiproliferative efficiency of adriamycin (ADR) because of the increasing accumulation of ADR in K562/ADR-resistant cell line. DMY could downregulate the expression of SORCIN and P-gp via the ERK/Akt pathways, whereas OND could not. In addition, it was proved that SORCIN suppressed ERK and Akt to inhibit P-gp by the silence of SORCIN, however, not vice versa. Finally, the combination of DMY, OND, and ADR led to G2/M cell cycle arrest and apoptosis via resuming P53 function and restraining relevant proteins express...Continue Reading

References

Jan 20, 2012·Current Medicinal Chemistry·A PalmeiraM M Pinto
Sep 10, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Gianni ColottiAndrea Ilari
Jun 3, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Shihui ChenMantian Mi
Nov 1, 2015·Biochemical Society Transactions·Richard Callaghan
Jan 7, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Chaojun XueKexin Liu
Jan 31, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Qing LiYan Shu
Feb 9, 2017·Archives of Toxicology·Thomas Efferth, Manfred Volm
May 27, 2017·Pharmacogenomics and Personalized Medicine·Ravindran Ankathil
Jun 8, 2017·Journal of Cellular Biochemistry·Yan ZhangKe-Xin Liu
Jun 27, 2017·International Journal of Pharmaceutics·Rezvan Yazdian-RobatiSeyed Mohammad Taghdisi
Jul 21, 2017·Cell Death & Disease·Ilaria GenoveseGianni Colotti

❮ Previous
Next ❯

Citations

Sep 10, 2019·Nucleic Acids Research·Jiayi YinFeng Zhu
May 17, 2019·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Yang DengMiao Yan
Nov 26, 2020·BMC Developmental Biology·Weiye SiDujuan Dong
Mar 7, 2021·Archives of Biochemistry and Biophysics·Dan WangWuqing Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.